Quinidine Sulfate Market

Executive Summary

Quinidine Sulfate Market was valued at US $457.48 million in 2021 and is projected to grow at 7.07% CAGR over the forecast period to reach US $689.07 million by 2027. Quinidine Sulfate Market represented US $58.39 million opportunity over 2019-2021 and estimated to create US $231.59 million opportunity in 2027 over 2021.

Quinidine Sulfate from Consainsights analyses the Quinidine Sulfate Market in the Life Sciences industry over the forecast period to 2027.

Quinidine Sulfate research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Quinidine Sulfate segmentation includes Route Of Administration, Application, End User, Region and Geography.

Based on the Route Of Administration, the Quinidine Sulfate analysis covers ORAL ADMINISTRATION, INTRAVENOUS ADMINISTRATION, OTHERS.

In Route Of Administration segment, ORAL ADMINISTRATION segment has highest cagr growth of 6.26%.

Based on the Application, the Quinidine Sulfate analysis covers ARRHYTHMIAS, MALARIA, OTHERS.

In Application segment, ARRHYTHMIAS segment has highest cagr growth of 6.26%.

Based on the End User, the Quinidine Sulfate analysis covers PEDIATRICS, ADULTS.

In End User segment, PEDIATRICS segment has highest cagr growth of 6.26%.

Based on the Region, the Quinidine Sulfate analysis covers EUROPE, ASIA-PACIFIC, LAMEA.

In Region segment, EUROPE segment has highest cagr growth of 6.26%.

Based on the region, the Quinidine Sulfate analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include ALLURE REMEDIES PVT. LTD., IPCA LABORATORIES, SANDOZ, WATSON LABORATORIES INC., INTAS PHARMACEUTICALS, SKYMAX LABORATORIES, CIPLA, BUCHLER GMBH COMPANY, LARK LABORATORIES, MERCK & CO., INC. and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Route Of Administration

Introduction

In 2021, ORAL ADMINISTRATION segment has the highest revenue of US $201.33 million and is expected to grow at CAGR of 6.26% by 2027 ORAL ADMINISTRATION segment has highest cagr growth of 6.26%.

ORAL ADMINISTRATION

ORAL ADMINISTRATION segment was valued at US $175.64 million in 2019 and is projected to grow at 6.26% CAGR over the forecast period to reach US $303.26 million by 2027. ORAL ADMINISTRATION segment represented US $25.70 million opportunity over 2019-2021 and estimated to create US $101.92 million opportunity in 2027 over 2021.

INTRAVENOUS ADMINISTRATION

INTRAVENOUS ADMINISTRATION segment was valued at US $137.09 million in 2019 and is projected to grow at 6.26% CAGR over the forecast period to reach US $236.70 million by 2027. INTRAVENOUS ADMINISTRATION segment represented US $20.06 million opportunity over 2019-2021 and estimated to create US $79.55 million opportunity in 2027 over 2021.

OTHERS

OTHERS segment was valued at US $86.36 million in 2019 and is projected to grow at 6.26% CAGR over the forecast period to reach US $149.12 million by 2027. OTHERS segment represented US $12.64 million opportunity over 2019-2021 and estimated to create US $50.12 million opportunity in 2027 over 2021.

Application

Introduction

In 2021, MALARIA segment has the highest revenue of US $185.88 million and is expected to grow at CAGR of 6.26% by 2027 ARRHYTHMIAS segment has highest cagr growth of 6.26%.

ARRHYTHMIAS

ARRHYTHMIAS segment was valued at US $150.09 million in 2019 and is projected to grow at 6.26% CAGR over the forecast period to reach US $259.15 million by 2027. ARRHYTHMIAS segment represented US $21.96 million opportunity over 2019-2021 and estimated to create US $87.10 million opportunity in 2027 over 2021.

MALARIA

MALARIA segment was valued at US $162.15 million in 2019 and is projected to grow at 6.26% CAGR over the forecast period to reach US $279.98 million by 2027. MALARIA segment represented US $23.72 million opportunity over 2019-2021 and estimated to create US $94.10 million opportunity in 2027 over 2021.

OTHERS

OTHERS segment was valued at US $86.85 million in 2019 and is projected to grow at 6.26% CAGR over the forecast period to reach US $149.95 million by 2027. OTHERS segment represented US $12.71 million opportunity over 2019-2021 and estimated to create US $50.40 million opportunity in 2027 over 2021.

End User

Introduction

In 2021, ADULTS segment has the highest revenue of US $240.30 million and is expected to grow at CAGR of 6.26% by 2027 PEDIATRICS segment has highest cagr growth of 6.26%.

PEDIATRICS

PEDIATRICS segment was valued at US $189.46 million in 2019 and is projected to grow at 6.26% CAGR over the forecast period to reach US $327.12 million by 2027. PEDIATRICS segment represented US $27.72 million opportunity over 2019-2021 and estimated to create US $109.94 million opportunity in 2027 over 2021.

ADULTS

ADULTS segment was valued at US $209.63 million in 2019 and is projected to grow at 6.26% CAGR over the forecast period to reach US $361.95 million by 2027. ADULTS segment represented US $30.67 million opportunity over 2019-2021 and estimated to create US $121.65 million opportunity in 2027 over 2021.

Region

Introduction

In 2021, EUROPE segment has the highest revenue of US $257.88 million and is expected to grow at CAGR of 6.26% by 2027 EUROPE segment has highest cagr growth of 6.26%.

EUROPE

EUROPE segment was valued at US $224.97 million in 2019 and is projected to grow at 6.26% CAGR over the forecast period to reach US $388.44 million by 2027. EUROPE segment represented US $32.91 million opportunity over 2019-2021 and estimated to create US $130.55 million opportunity in 2027 over 2021.

ASIA-PACIFIC

ASIA-PACIFIC segment was valued at US $95.59 million in 2019 and is projected to grow at 6.26% CAGR over the forecast period to reach US $165.04 million by 2027. ASIA-PACIFIC segment represented US $13.98 million opportunity over 2019-2021 and estimated to create US $55.47 million opportunity in 2027 over 2021.

LAMEA

LAMEA segment was valued at US $78.53 million in 2019 and is projected to grow at 6.26% CAGR over the forecast period to reach US $135.60 million by 2027. LAMEA segment represented US $11.49 million opportunity over 2019-2021 and estimated to create US $45.57 million opportunity in 2027 over 2021.